Aberrant phenotype of plasmacytoid monocytes in acute myeloid leukemia.
Boveri
Emanuela
E
Institute of Surgical Pathology, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy. embover@tin.it
Castagnola
Carlo
C
Castello
Alessandro
A
Magrini
Umberto
U
D015703:Antigens, CD / Q000032:analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy; D001853:Bone Marrow / Q000473:pathology*; D002454:Cell Differentiation; D002999:Clone Cells / Q000473:pathology; D003561:Cytarabine / Q000008:administration & dosage; D017809:Fatal Outcome; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage / Q000627:therapeutic use; D016130:Immunophenotyping; D015470:Leukemia, Myeloid, Acute / Q000150:complications / Q000473:pathology*; D008297:Male; D008533:Megakaryocytes / Q000473:pathology; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D009000:Monocytes / Q000737:chemistry / Q000473:pathology*; D009363:Neoplasm Proteins / Q000032:analysis; D014411:Neoplastic Stem Cells / Q000737:chemistry / Q000473:pathology*
D015703:Antigens, CD; D009363:Neoplasm Proteins; D003561:Cytarabine; D008727:Methotrexate; D015255:Idarubicin